CAMBRIDGE, Mass.– Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, has signed a memorandum of understanding (MoU) with Embryyo Technologies, one of India’s leading medical device innovation studios, to pursue opportunities in the global AI-enabled medical device market.
The collaboration seeks to combine Vyome’s healthcare industry experience and access to global capital markets with Embryyo’s track record in medical technology innovation. Together, the companies plan to develop and commercialize smart medical devices aimed at transforming disease management and patient care.
“Vyome’s vision is to partner with the smartest talent tackling the biggest healthcare markets along the U.S.-India corridor and across our three pillars of pharma, AI, and medical devices,” said Krishna Gupta, Chairman of Vyome Holdings. “AI-enabled medical devices represent a large opportunity, and the Embryyo team — helmed by IIT alums — has been working in this sector for a decade. We will be working with them to identify the specific initiatives on which we will partner.”
Embryyo Technologies, co-founded by Nishant Kumar, has been building a portfolio of devices across interventional oncology, surgical innovation, wearables, and drug delivery systems.
“We are excited about this partnership with Vyome as we have a shared vision,” Kumar said. “Our mission is to push the frontiers of medicine and elevate standards of care globally, and Vyome’s access to capital and the U.S. healthcare ecosystem will accelerate that journey.”
As part of the collaboration, the companies announced plans to host a global AI-enabled medical device innovation forum focused on the U.S.-India healthcare corridor. The MoU is non-binding and subject to further conditions.
